Su-Yeon Yu1, Boram Lee2, Treasure M McGuire1,3,4, Hye-Jae Lee5, Samantha A Hollingworth1. 1. School of Pharmacy, The University of Queensland, Brisbane, Australia. 2. Graduate School of Public Health, Seoul National University, Seoul, South Korea. dheart14@snu.ac.kr. 3. Mater Pharmacy, Mater Health, Brisbane, Australia. 4. Faculty of Health Sciences and Medicine, Bond University, Robina, Gold Coast, Australia. 5. Health Insurance Policy Research Institute, National Health Insurance Service, Wonju, South Korea.
Abstract
PURPOSE: The study's aim was to compare the use of proton pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RAs) and mucoprotective medicines (MPs) used for gastric acid-related disorders (GARD) in Australia and South Korea (Korea) from 2004 to 2017. METHODS: Prescription data for PPIs, H2RAs and MPs for Australian outpatients were extracted from the Australian Statistics on Medicines annual reports, with dose-specific and expenditure data obtained from Medicare. Similar data were obtained from Korean National Health Insurance Service claims data. We analysed the volume and expenditure of medicines use annually using the defined daily dose per 1,000 population per day. We calculated which medicines accounted for 90% of use and estimated the proportions of use for low- and high-dose PPIs. RESULTS: While total utilisation for GARD medicines increased over time in both countries, patterns of use differed. Overall, use was somewhat higher in Australia but increased more rapidly in Korea. PPIs were used more extensively in Australia, while more MPs and H2RAs were used in Korea. Expenditure and use of low-dose PPIs is escalating in Korea. CONCLUSION: There were substantial differences in the use of GARD medicines in Australia and Korea over 14 years. Both countries face similar challenges to promote rational medicines use and contain medical care costs. The discrepant prescribing patterns can be attributed to differences in healthcare systems, pharmaceutical policies and demographics. This study provides a baseline to influence more rational use of these medicines. It provides insight into medicines policies for other countries that face similar challenges.
PURPOSE: The study's aim was to compare the use of proton pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RAs) and mucoprotective medicines (MPs) used for gastric acid-related disorders (GARD) in Australia and South Korea (Korea) from 2004 to 2017. METHODS: Prescription data for PPIs, H2RAs and MPs for Australian outpatients were extracted from the Australian Statistics on Medicines annual reports, with dose-specific and expenditure data obtained from Medicare. Similar data were obtained from Korean National Health Insurance Service claims data. We analysed the volume and expenditure of medicines use annually using the defined daily dose per 1,000 population per day. We calculated which medicines accounted for 90% of use and estimated the proportions of use for low- and high-dose PPIs. RESULTS: While total utilisation for GARD medicines increased over time in both countries, patterns of use differed. Overall, use was somewhat higher in Australia but increased more rapidly in Korea. PPIs were used more extensively in Australia, while more MPs and H2RAs were used in Korea. Expenditure and use of low-dose PPIs is escalating in Korea. CONCLUSION: There were substantial differences in the use of GARD medicines in Australia and Korea over 14 years. Both countries face similar challenges to promote rational medicines use and contain medical care costs. The discrepant prescribing patterns can be attributed to differences in healthcare systems, pharmaceutical policies and demographics. This study provides a baseline to influence more rational use of these medicines. It provides insight into medicines policies for other countries that face similar challenges.
Authors: Brian Godman; William Shrank; Morten Andersen; Christian Berg; Iain Bishop; Thomas Burkhardt; Kristina Garuoliene; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Diane McGinn; Vita Samaluk; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; Lesley Tilson; F Cankat Tulunay; Vera Vlahović-Palčevski; Kamila Wendykowska; Björn Wettermark; Corinne Zara; Lars L Gustafsson Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2010-12 Impact factor: 2.217
Authors: Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett Journal: Postgrad Med J Date: 2007-01 Impact factor: 2.401
Authors: Chris A Liacouras; Jonathan M Spergel; Eduardo Ruchelli; Ritu Verma; Maria Mascarenhas; Edisio Semeao; Jonathan Flick; Janice Kelly; Terry Brown-Whitehorn; Petar Mamula; Jonathan E Markowitz Journal: Clin Gastroenterol Hepatol Date: 2005-12 Impact factor: 11.382
Authors: Barbara Farrell; Kevin Pottie; Wade Thompson; Taline Boghossian; Lisa Pizzola; Farah Joy Rashid; Carlos Rojas-Fernandez; Kate Walsh; Vivian Welch; Paul Moayyedi Journal: Can Fam Physician Date: 2017-05 Impact factor: 3.275
Authors: Amy T Page; Michael O Falster; Melisa Litchfield; Sallie-Anne Pearson; Christopher Etherton-Beer Journal: Med J Aust Date: 2019-06-20 Impact factor: 7.738